Skip to main content
. 2014 Feb;58(2):1167–1178. doi: 10.1128/AAC.01855-13

TABLE 2.

Activities of compounds against cruzipain-ΔC and human cathepsin enzymes

Compound Mean ± SDa IC50 (n)
Reference
Cruzipain-ΔC CatB CatF CatK CatL CatS CatV
Cz003 (weak, neutral) 3,700 (2) b 1 ± 0.3 (3) 5,990 ± 1,380 (3)
Cz001 (moderate, neutral) 170 (2) <0.3 (2) 2,253 (2)
Cz002 (potent, neutral) 1.2 (2) 692 ± 177 (3) 8 ± 2 (3) 0.7 ± 0.7 (2) 104 ± 52 (4) 40 ± 12 (4)
Cz005 (potent, basic) 2.4 (2) 12 ± 4 (4) <0.2 (7) 62 ± 25 (5) 16 ± 2 (4)
K777 (irreversible) 3.5 (2) 9 (2) 3 (2) 1.8 (2) <0.2 (3) <0.2 (2)
Cz007 (potent, neutral) 1.1 (2) 9 ± 2 (9) 4 ± 1 (8) <0.5 (1) 49 ± 19 (9) 1.6 ± 0.2 (8) 2 (1) 29
Cz008c (potent, basic) 1.8 (2) 584 ± 304 (4) 53 ± 21 (3) <0.005d (1) 109 ± 11 (4) 414 ± 141 (4) 30
Odanacatib (cathepsin K) 1,034 0.2 2,995 60 27
a

Each entry is the mean concentration ± the standard deviation (with n in parentheses), unless otherwise indicated. Values may be slightly different than those reported by Beaulieu et al. (29) and Black et al. (30) due to additional testing (higher n values).

b

—, not tested.

c

Cz008 is the single diastereomer of Cz005 with the trifluoromethyl side chain stereochemistry resolved.

d

For a description of the low protein assay, see Black et al. (30).